SecBot SecBot
8-K ·Filed Apr 27, 2026

ARMP

Armata Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed6mo ago SEC0001104659-26-048997
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

Monitor future clinical and commercial strategy updates for signs of accelerated development timelines or partnership activity, as Gilmer's expertise may influence Armata's path to market for its phage-based pipeline. No immediate financial or operational changes are expected from this appointment.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.00
T+0 close · Apr 27, 2026 · via day close
Latest settled
−52.36%
T+60 · $5.24
Vs SPY
−57.14%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $11.00entry
  2. T+1 · 7mo ago −11.27%α −10.79% · $9.76
  3. T+5 · 7mo ago −10.45%α −10.85% · $9.85
  4. T+20 · 6mo ago −25.73%α −30.68% · $8.17
  5. T+60 · 4mo ago −52.36%α −57.14% · $5.24
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Armata Pharmaceuticals appointed Dr. Daniel Gilmer, a biopharmaceutical commercial executive with experience at Pfizer and McKinsey, to its Board of Directors. The move adds expertise in commercialization of anti-infectives, including leadership in the U.S. launch of PAXLOVID, to support Armata's development of bacteriophage therapeutics.

Key Facts

  • Dr. Daniel Gilmer, Ph.D., appointed to Board of Directors effective April 24, 2026
  • Gilmer previously served as Senior Director, Commercial Quality U.S. Team Lead at Pfizer since February 2025
  • He led the U.S. launch of PAXLOVID and has experience in commercial strategy, patient access, and antimicrobial resistance
  • Gilmer is an equal co-inventor on the patent for Exebacase, a first-in-class bacteriophage lysin
  • He will receive an option award to purchase 51,280 shares of common stock, vesting over three years
  • No other arrangements or understandings exist with Gilmer beyond standard director compensation

Financial Impact

Minimal immediate financial impact. Director compensation includes $40,000 annual cash retainer and expected option award for 51,280 shares.

share-based compensationboard compositiongovernance

Risk Factors

  • Integration of new board member may lead to strategic shifts
  • No replacement named for any departing executive, indicating potential governance continuity
  • Biotech clinical-stage companies face high execution risk in drug development

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-048997
Document: tm2612716d1_ex99-1.htm0001104659-26-048997
Document: 0001104659-26-048997-index-headers.html0001104659-26-048997
Document: 0001104659-26-048997-index.html0001104659-26-048997
Document: 0001104659-26-048997.txt0001104659-26-048997

Track record

6 reports on ARMP

Performance horizon

1 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +43.90% at T+60 after the May 13, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $3.87 Now $2.99 −22.74% settles Dec 14
  2. Sep 23, 20267w ago 8-K Bullish 5/10 Entry $3.64 to $3.06 Now $2.99 −17.86% ▼ −15.93% −16.62% vs SPY
  3. Sep 14, 20269w ago 8-K Bullish 7/10 Entry $5.55 to $3.63 Now $2.99 −46.13% ▼ −34.59% −36.86% vs SPY
  4. Jul 20, 202617w ago 8-K Bullish 5/10 Entry $5.06 to $4.48 Now $2.99 −40.91% ▼ −11.46% −15.58% vs SPY
  5. May 13, 202626w ago 8-K Bearish 6/10 Entry $8.20 to $7.58 Now $2.99 +63.54% ▲ +7.56% +6.70% vs SPY
  6. Apr 27, 202629w ago 8-K Neutral 3/10 Viewing Entry $11.00 to $8.17 Now $2.99 −72.82% ▼ −25.73% −30.68% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens in 9h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026